MITSUBISHI-HITACHI-POWER
2.4.2020 04:02:07 CEST | Business Wire | Press release
Mitsubishi Hitachi Power Systems, Ltd. (MHPS) has begun commissioning of T-Point 2, its new combined cycle power plant validation facility at Takasago Works in Hyogo Prefecture, Japan. Replacing the iconic T-Point, the facility will accelerate MHPS’ industry-leading technology and enable more robust validation of advanced-class gas turbines (ACGTs) such as the 1650°C-class JAC model and 1700°C-class ultrahigh-temperature models. Like its predecessor, T-Point 2 stands apart as the only facility in the world that performs full-scale long-term reliability verification for gas turbines. Connected to the actual grid, it is the only plant of its type in the world to function as both a technology demonstrator and an electric power producer and supplier. Also housed within Takasago Works are centers for R&D, design, manufacturing, and short-term component testing.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200401005834/en/
“Through the years, we have proven our ability to develop and manufacture the most cutting-edge solutions for the power generation industry,” said Mr. Ken Kawai, President and CEO, MHPS. “Building on the legacy of the original T-Point, T-Point 2 will enable us to widen our footprint as the preferred solutions partner to meet ever-changing power generation requirements around the world.”
Engineering the next generation of gas turbines
Once commercial operations begin in July 2020, T-Point 2 is expected to achieve power output of over 566 MW (60Hz), with nearly 64% efficiency, 99.5% reliability and a world-first turbine inlet temperature of 1650°C – raising industry standards for gas turbine combined cycle performance globally. This improved performance is possible due to the advanced engineering of the upgraded J-Series Air-Cooled (JAC) model, which is the first gas turbine being validated at T-Point 2.
The new facility features a triple-casing steam turbine, augmenting overall system efficiency through a multiplier effect with the JAC gas turbine. This greater efficiency reduces carbon emissions and heat loss, significantly reducing the environmental impact of T-Point 2.
“The prototype validation system established by MHPS has given our customers the clear assurance that they are receiving the highest caliber and most reliable energy solutions in the market,” said Mr. Junichiro Masada, Senior Vice President and Senior General Manager of Gas Turbine Technology & Products Integration Division, MHPS. “The launch of T-Point 2 is testament to MHPS’ commitment to deliver industry-leading power generation technology and customer service underpinned by best-in-class methods for performance and durability verification.”
MHPS will use the facility to conduct validation of the next-generation 1700°C-class ultrahigh-temperature gas turbines, steam turbine upgrades, air-cooled condenser technology, generators, and static frequency converters.
Bringing power generation to the digital age
Work is underway to install and train advanced artificial intelligence technology at T-Point 2, which will feature the MHPS-TOMONI®
suite of digital solutions. During the 8,000 hour durability demonstration period, MHPS will also be training its AI apps, allowing T-Point 2 to eventually become the world’s first autonomous combined cycle power plant. This will catapult power generation into a future where digital technologies are fully integrated into plant operations, allowing plant owners to leverage data to optimize performance, enable condition-based predictive maintenance for equipment, selectively automate operation and maintenance (O&M) decision-making, and reduce risk.
With these building blocks, MHPS will remotely monitor and manage total plant performance; remotely operate the plant in coordination with grid and fleet-wide energy management objectives; and utilize sensor and control system data to make smarter operation decisions in real time. MHPS-TOMONI® solutions powered by advanced technologies such as artificial intelligence and machine learning will enable MHPS to automate O&M decision-making to maximize the profitability of existing and future GTCC plants.
About Mitsubishi Hitachi Power Systems, Ltd.
Mitsubishi Hitachi Power Systems, Ltd. (MHPS), headquartered in Yokohama, Japan, is a joint venture formed in February 2014 by Mitsubishi Heavy Industries, Ltd. and Hitachi, Ltd. integrating their operations in thermal power generation systems and other related businesses. MHPS today ranks among the world’s leading suppliers of equipment and services to the power generation market, backed by 100 billion yen in capital and approximately 20,000 employees worldwide. The Company’s products include GTCC (gas turbine combined-cycle) and IGCC (integrated coal gasification combined-cycle) power plants, gas/coal/oil-fired (steam) power plants, boilers, generators, gas and steam turbines, geothermal power plants, AQCS (air quality control systems), power plant peripheral equipment and solid-oxide fuel cells (SOFC). For more information, please visit the Company's website at https://www.mhps.com
. Follow us at https://twitter.com/MHPS_Global
, or http://www.linkedin.com/showcase/mhps
View source version on businesswire.com: https://www.businesswire.com/news/home/20200401005834/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release
The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release
Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
